Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
Open Access
- 12 November 2021
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 11 (3), 47-55
- https://doi.org/10.17650/2222-1468-2021-11-3-47-55
Abstract
Among the differentiated forms of thyroid cancer, the least favorable clinical prognosis is observed in radioiodine-refractory differentiated thyroid cancer. The next step in the treatment of such patients is effective and potential toxicity multi-kinase inhibitors. Often, patients with refractory radioiodine thyroid cancer have a high tumor burden, various symptoms and comorbidity; therefore, clinicians may decide to initiate therapy at a reduced starting dose. In a randomized clinical multicenter study 211 higher objective response rate at 24th weeks were observed in the group of patients receiving lenvatinib at a dose of 24 mg per day compared with patients receiving Lenvatinib at a dose of 18 mg per day, while the difference in the incidence of serious adverse events grade 3–4 (SAE) at the 24th week of treatment were insignificant. Real clinical practice differs from randomized clinical trials regarding to the population of patients, their selection for treatment, adherence to drug dosage regimens, follow-ups, etc. In this paper, we analyzed the world and domestic clinical practice of the treatment of radioiod-refractory thyroid cancer and assessed the effect of the starting dose of lenvatinib and the duration of breaks in its administration on the effectiveness and safety of therapy.Keywords
This publication has 9 references indexed in Scilit:
- 426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mgAnnals of Oncology, 2020
- Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in JapanAdvances in Therapy, 2020
- Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United StatesAdvances in Therapy, 2020
- Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in ItalyEuropean Journal of Cancer, 2019
- Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancerEuropean Journal of Cancer, 2019
- Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT TrialJournal of Clinical Oncology, 2017
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerThe New England Journal of Medicine, 2015
- Definition and management of radioactive iodine-refractory differentiated thyroid cancerThe Lancet Diabetes & Endocrinology, 2014
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014